Delayed presentation of biopsy-proven eosinophilic myocarditis following COVID-19 mRNA vaccine

Authors

  • Chaitra Janga Department of Internal Medicine, Jefferson Abington Hospital, Abington, PA, USA
  • Tirth Patel Department of Internal Medicine, Jefferson Abington Hospital, Abington, PA, USA
  • Hussam Al Hennawi Department of Internal Medicine, Jefferson Abington Hospital, Abington, PA, USA
  • Sarin Atam Department of Internal Medicine, Jefferson Abington Hospital, Abington, PA, USA
  • Shreeja Shah Department of Internal Medicine, Jefferson Abington Hospital, Abington, PA, USA
  • Ifrah Naeem Department of Internal Medicine, Jefferson Abington Hospital, Abington, PA, USA
  • Rahat Memon Department of Internal Medicine, Jefferson Abington Hospital, Abington, PA, USA
  • Donald C Haas Department of Internal Medicine, Jefferson Abington Hospital, Abington, PA, USA

DOI:

https://doi.org/10.21542/gcsp.2023.10

Abstract

Myopericarditis associated with COVID-19 mRNA vaccines has been recognized as an uncommon adverse reaction, especially among young, healthy adult males. Eosinophilic myocarditis is a rare form of inflammation reflecting a hypersensitivity reaction following an inciting event commonly caused by drugs including vaccines. Eosinophilic myocarditis, a subtype of myocarditis, is characterized by eosinophilic myocardial infiltrates. It is usually accompanied by systemic eosinophilia in the form of a drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome and is rarely associated with myocyte fibrosis and/or necrosis. In this report, we present a case of biopsy-proven eosinophilic myocarditis in a 24-year-old male patient, likely secondary to COVID-19 mRNA vaccination. To our knowledge, this is the first report to describe delayed eosinophilic myocarditis following the COVID-19 mRNA vaccine. Clinicians should be aware of possible delayed presentation to avoid associated morbidity.

Downloads

Published

2023-05-08

Issue

Section

Images in cardiology